| Literature DB >> 28558679 |
Anwar Zeb1, Farhat Ullah1, Muhammad Ayaz1, Sajjad Ahmad1, Abdul Sadiq2.
Abstract
BACKGROUND: Since long, natural sources have been explored for possible managements of various diseases. In this context, the study is designed to evaluate Isodon rugosus Wall. ex Benth for biological potentials including antibacterial, anthelmintic, insecticidal, anti-termites and anti-Pharaoh activities followed by GC-MS analysis of active fraction to identify various bioactive compounds.Entities:
Keywords: Anthelmintic; Anti-Pharaoh; Anti-termites; Antibacterial; Ascaridia galli; GC-ms; Isodon rugosus; MICs
Mesh:
Substances:
Year: 2017 PMID: 28558679 PMCID: PMC5450350 DOI: 10.1186/s12906-017-1798-9
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
List of all compounds identified in the GC-MS analysis of ethyl acetate fraction of Isodon rugosus
| S. No | Compound Label | RT | Name | Formula | Hits (DB) |
|---|---|---|---|---|---|
| 1. | Cyclohexanone (CAS) $$ Anon $$ Anone $$ Nadone $$ Hexanon $$ Sextone | 3.858 | Cyclohexanone | C6H10O | 10 |
| 2. | Ethanol, 2-ethoxy-, acetate (CAS) $$ 2-Ethoxyethyl acetate $$ Oxitol acetate | 3.936 | Oxitol acetate | C6H12O3 | 10 |
| 3. | Cyclopentane, 1,1,3,4-tetramethyl-, trans- (CAS) | 4.726 | Nf | C9H18 | 10 |
| 4. | 1-(4-Tosyloxybutyl)-3-(1-methoxy-1-methylethoxy)clopentene | 4.842 | Nf | C20H30O5S | 1 |
| 5. | (1.alpha.,5.alpha.,6.alpha.,7.alpha.)-6,7-(Z,E)-Dipropenyl-3-oxabicyclo[3.2.... | 5.428 | Nf | C12H18O | 6 |
| 6. | Butanedioic acid, ethyl methyl ester (CAS) $$ 1-Ethyl 4-methyl succinate | 7.031 | Nf | C7H12O4 | 10 |
| 7. | N-Butylpropargylamine | 7.156 | Butylpropargylamine | C7H13N | 10 |
| 8. | 2-Cyclohexen-1-one, 3,5,5-trimethyl- (CAS) $$ 3,5,5-Trimethyl-2-cyclohexenone | 7.366 | Nf | C9H14O | 10 |
| 9. | Succinic acid, butyl ethyl ester | 8.151 | Nf | C10H18O4 | 10 |
| 10. | Butanedioic acid (CAS) $$ Succinic acid (CAS) $$ Asuccin $$ Amber acid | 8.234 | Amber acid | C4H6O4 | 10 |
| 11. | Undecane, 4-methyl- (CAS) $$ 4-Methylundecane $$ 4 - methyl - undecane | 8.456 | Nf | C12H26 | 10 |
| 12. | 1-(1,1-dimethyl-2-propenyl)-1-cyclohexene | 10.256 | Nf | C11H18 | 10 |
| 13. | Dodecane, 2-methyl- (CAS) $$ 2-Methyldodecane $$ 11-Methyldodecane | 11.258 | Nf | C13H28 | 10 |
| 14. | (+)-(E)-N,N-Di-tert-butoxycarbonyl-1,3-diphenylprop-2-enyamine | 12.008 | Nf | C25H31NO4 | 1 |
| 15. | Benzene, 1-(bromomethyl)-3-nitro- $$ m-(Bromomethyl)nitrobenzene | 12.284 | Nf | C7H6BrNO2 | 10 |
| 16. | rac-.gamma.(2)-muurolene | 12.418 | rac-γ(2)-muurolene | C16H24 | 10 |
| 17. | Decane, 3-bromo- $$ 3-Bromodecane # | 12.54 | Nf | C10H21Br | 1 |
| 18. | Acetic Acid 2-(4-Hydroxyphenyl)ethyl Ester | 13.523 | Nf | C10H12O3 | 10 |
| 19. | Tetradecane, 1-chloro- $$ Myristyl chloride $$ Tetradecyl chloride | 13.738 | Myristyl chloride | C14H29Cl | 10 |
| 20. | alpha.-Amorphene $$. ALPHA. AMORPHENE $$ 6.alpha.-Cadina-4,9-diene, (−)- | 14.153 | α-Amorphene | C15H24 | 10 |
| 21. | alpha.-Copaene $$ Copaene (CAS) $$ Copaen $$ (−)-.alpha.-Copaene | 14.516 | Copaen | C15H24 | 10 |
| 22. | alpha.-Cadinol $$ Cadin-4-en-10-ol $$ l-.alpha.-Cadinol $$ 10-.ALPHA.-CADINOL | 14.64 | α-Cadinol | C15H26O | 10 |
| 23. | 4-((1E)-3-Hydroxy-1-propenyl)-2-methoxyphenol | 15.859 | Nf | C10H12O3 | 10 |
| 24. | (−)-Loliolide $$ Loliolide $$ Loliolid $$ Digiprolactone $$ Calendin | 16.428 | Loliolide | C11H16O3 | 2 |
| 25. | Neophytadiene $$ 7,11,15-TRIMETHYL,3-METHYLENE-1-HEXADECENE | 17.314 | Neophytadiene | C20H38 | 10 |
| 26. | R-7-endo-p-phenylbenzoyloxy-6-anti-(.beta.-phenylethenyl)-2-oxa-bicyclo[3.3.... | 17.447 | Nf | C27H24O3 | 1 |
| 27. | 2-Hexadecen-1-ol, 3,7,11,15-tetramethyl-, [R-[R*,R*-(E)]]- (CAS) | 18.25 | Nf | C20H40O | 10 |
| 28. | Hexadecanoic acid, methyl ester (CAS) $$ Methyl palmitate $$ Uniphat A60 | 19.316 | Methyl palmitate | C17H34O2 | 10 |
| 29. | n-Hexadecanoic acid $$ Hexadecanoic acid $$ n-Hexadecoic acid $$ Palmitic acid | 20.498 | Palmitic acid | C16H32O2 | 10 |
| 30. | Hexadecanoic acid, ethyl ester (CAS) $$ Ethyl palmitate $$ Ethyl hexadecanoate | 21.386 | Ethyl palmitate | C18H36O2 | 10 |
| 31. | CIS-11,14,17-EICOSATRIENOIC ACID ME | 25.548 | Nf | C21H36O2 | 10 |
| 32. | Phytol $$ 2-Hexadecen-1-ol, 3,7,11,15-tetramethyl-, [R-[R*,R*-(E)]]- | 26.041 | Phytol | C20H40O | 10 |
| 33. | 17-Octadecynoic acid | 27.132 | Nf | C18H32O2 | 10 |
| 34. | Linoleic acid ethyl ester $$ Ethyl linoleate $$ Ethyl linolate $$ Mandenol | 27.616 | Mandenol | C20H36O2 | 10 |
| 35. | Acetic acid, chloro-, hexadecyl ester $$ Chloro-acetic acid hexadecyl ester | 27.817 | Nf | C18H35ClO2 | 10 |
| 36. | 9,12,15-Octadecatrienoic acid, methyl ester, (Z,Z,Z)- $$ Methyl linolenate | 27.831 | Methyl linolenate | C19H32O2 | 10 |
| 37. | Octadecanoic acid, ethyl ester (CAS) $$ Ethyl stearate $$ Ethyl octadecanoate | 28.617 | Ethyl stearate | C20H40O2 | 10 |
| 38. | Neophytadiene $$ 7,11,15-TRIMETHYL,3-METHYLENE-1-HEXADECENE | 29.321 | Neophytadiene | C20H38 | 10 |
| 39. | Hexadecanoic acid, ethyl ester (CAS) $$ Ethyl palmitate $$ Ethyl hexadecanoate | 33.473 | Ethyl palmitate | C18H36O2 | 10 |
| 40. | Naphthalene, 1,2,3,4-tetrahydro-1-isopropyl-1,2,4,4,7-pentamethyl- | 35.4 | Nf | C18H28 | 1 |
| 41. | 3,4,8-trimethyl-9-oxy-1-trimethylsilyloxybicyclo[4.3.1]non-1-ene | 35.883 | Nf | C15H26O2Si | 10 |
| 42. | Di-(2-ethylhexyl)phthalate $$ 1,2-BENZENEDICARBOXYLIC ACID | 36.417 | Nf | C24H38O4 | 10 |
| 43. | Hinokione $$ (+)-Hinokione | 36.604 | Hinokione | C20H28O2 | 10 |
| 44. | [ | 37.056 | Nf | C15H14N4O3S | 1 |
| 45. | Hinokiol $$ (+)-Hinokiol | 37.242 | Hinokiol | C20H30O2 | 4 |
| 46. | 7,8,9-Trimethoxy-4,5-dihydro-1H-benzo[g]indazole | 39.446 | Nf | C14H16N2O3 | 1 |
| 47. | 13b–methyl-3-propyl-1,3,4,6,7,8,13,13b–octahydro-2 h-pyrido[1′,2′:1,2]azepino... | 40.14 | Nf | C20H28N2 | 10 |
| 48. | 7,7-Dimethyl-6,7-diihydro-5H-benzo[f]pyrano[2,3-h]quinoxaline | 40.607 | Nf | C17H16N2O | 2 |
| 49. | 3-[(3,4-dimethoxy-benzylamino)-methyl]-8a–methyl-5-methylene-decahydro-napht... | 40.934 | Nf | C24H33NO4 | 1 |
| 50. | 1-Hexadecanol (CAS) $$ Cetal $$ Ethal $$ Ethol $$ Cetanol $$ Cetylol $$ Adol 52 | 43.494 | Cetylol | C16H34O | 10 |
| 51. | dl-.alpha.-Tocopherol $$ (.+/−.)-.alpha.-Tocopherol $$ Vitamin E | 45.326 | Vitamin E | C29H50O2 | 7 |
| 52. | 1,3-Diethyladamantane | 49.926 | Nf | C14H24 | 2 |
| 53. | Stigmasta-5,22-dien-3-ol, acetate, (3.beta.)- $$ Stigmasterol acetate | 50.163 | Stigmasterol acetate | C31H50O2 | 6 |
| 54. | Viminalol $$ Urs-12-en-3-ol, (3.beta.)- (CAS) $$ .alpha.-Amyrin $$ ALPHA-AMYRIN | 50.299 | Viminalol | C30H50O | 10 |
| 55. | 4,6-Dimethoxy-2,3-diphenyl-7-(1-pyrrolin-2-yl)indole | 51.53 | Nf | C26H24N2O2 | 3 |
| 56. | Stigmast-4-en-3-one $$ 4-Stigmasten-3-one $$ Sitostenone | 51.622 | Sitostenone | C29H48O | 1 |
| 57. | 4-Hydroxy-1,2-dimethoxyanthraquinone | 62.475 | Nf | C16H12O5 | 3 |
Various parameters major compounds in GC-MS of ethyl acetate fraction of Isodon rugosus
| S.No | RT | Height | Height % | Area | Area % | Area Sum % | Base Peak m/z | Width |
|---|---|---|---|---|---|---|---|---|
| 1. | 3.857 | 54,336 | 6.81 | 66,940 | 1.91 | 0.65 | 55.1 | 0.05 |
| 2. | 3.938 | 57,317 | 7.19 | 70,955 | 2.03 | 0.69 | 43.1 | 0.054 |
| 3. | 7.029 | 40,590 | 5.09 | 80,194 | 2.29 | 0.78 | 115 | 0.07 |
| 4. | 7.367 | 581,648 | 72.95 | 1E + 06 | 29.17 | 9.92 | 82 | 0.107 |
| 5. | 8.15 | 74,641 | 9.36 | 122,166 | 3.49 | 1.19 | 101 | 0.054 |
| 6. | 9.698 | 44,503 | 5.58 | 70,074 | 2 | 0.68 | 70.1 | 0.06 |
| 7. | 11.73 | 62,937 | 7.89 | 90,543 | 2.59 | 0.88 | 93 | 0.05 |
| 8. | 21.386 | 542,089 | 67.99 | 2E + 06 | 66.56 | 22.64 | 88 | 0.171 |
| 9. | 27.829 | 797,352 | 100 | 3E + 06 | 100 | 34.02 | 79 | 0.178 |
| 10. | 29.319 | 754,398 | 94.61 | 3E + 06 | 78.36 | 26.66 | 68.1 | 0.137 |
Fig. 1Chromatogram of Ethyl acetate fraction of Isodon rugosus
Fig. 2Bioactive compounds identified in the ethyl acetate fraction of Isodon rugosus
Fig. 3Mass spectra of bioactive compounds in ethyl acetate fraction of Isodon rugosus
Antibiotic Susceptibility pattern of selected bacterial strains to different antibiotic groups
| Bacterial strains | Diameter of the inhibitory zone (mm) Mean ± SEM ( | |||||
|---|---|---|---|---|---|---|
| Ciprofloxacin | Cefixime | Amoxycillin | Gentamycin | Cephradine | Cloxacillin | |
|
| 24.67 ± 1.20 | 18.33 ± 0.88 | 07.67 ± 0.67 | 26.67 ± 0.67 | 06.67 ± 0.88 | 09.33 ± 0.33 |
|
| 19.00 ± 0.57 | 06.67 ± 0.67 | 08.00 ± 0.57 | 22.00 ± 0.57 | 08.67 ± 0.88 | 06.67 ± 1.20 |
|
| 22.33 ± 0.88 | 16.67 ± 1.20 | 07.67 ± 1.20 | 20.67 ± 1.20 | 10.33 ± 1.45 | 08.33 ± 0.33 |
|
| 16.33 ± 0.33 | 12.33 ± 0.88 | 09.33 ± 0.88 | 26.67 ± 0.67 | 14.00 ± 1.15 | 06.67 ± 0.67 |
|
| 18.67 ± 1.20 | 06.67 ± 0.33 | 10.67 ± 0.33 | 27.33 ± 0.88 | 10.00 ± 0.57 | 12.33 ± 0.88 |
|
| 26.67 ± 0.67 | 08.33 ± 0.33 | 14.00 ± 0.57 | 29.00 ± 0.57 | 12.33 ± 0.88 | 08.00 ± 0.57 |
|
| 23.00 ± 0.57 | 11.67 ± 0.67 | 11.33 ± 0.88 | 26.00 ± 1.15 | 12.67 ± 0.67 | 09.67 ± 1.20 |
|
| 23.33 ± 0.33 | 26.67 ± 1.20 | 7.67 ± 1.20 | 24.33 ± 0.33 | 10.00 ± 1.15 | 07.00 ± 1.15 |
Antibacterial activity of Isodon rugosus against various bacterial strains expressed in mm as ZOI
| Samples |
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
| Ir.Cr | 17.2 ± 0.37 | 9.1 ± 0.34 | 7.2 ± 0 .55 | --- | 28.2 ± 0.40 | 18.2 ± 0.35 | 9.3 ± 0.31 | 21.3 ± 0.36 |
| Ir.Hex | 07.3 ± 0.34 | 9.1 ± 0.52 | --- | 7.1 ± 0.49 | 18.2 ± 0.37 | 17.2 ± 0.37 | 8.3 ± 0.25 | 23.3 ± 0.36 |
| Ir.Cf | 11.2 ± 0.32 | 19.2 ± 0.47 | 7.1 ± 0.26 | --- | 6.1 ± 0.46 | 15.3 ± 0.35 | 9.2 ± 0.31 | 19.3 ± 0.39 |
| Ir.EtAc | 9.2 ± 0.40 | 29.3 ± 0.28 | 21.2 ± 0.40 | 17.1 ± 0.46 | 28.2 ± 0.35 | 18.2 ± 0.40 | 7.1 ± 0.46 | 8.2 ± 0.37 |
| Ir.Aq | 21.2 ± 0.31 | 9.2 ± 0.31 | --- | 13.2 ± 0.20 | 9.2 ± 0.40 | 9.2 ± 0.40 | 17.2 ± 0.37 | --- |
| Ir.Sp | 18.2 ± 0.43 | 27.2 ± 0.23 | 24.1 ± 0.52 | 26.3 ± 0.34 | 8.2 ± 0.37 | 21.3 ± 0.39 | 9.2 ± 0.40 | 19.3 ± 0.38 |
| Ir.Flv | 33.1 ± 0.49 | 16.2 ± 0.54 | 12.2 ± 0.54 | 31.3 ± 0.31 | 16.2 ± 0.23 | 27.3 ± 0.35 | 19.2 ± 0.38 | 13.2 ± 0.45 |
| Ceft | 35.2 ± 0.37 | 31.1 ± 0.34 | 9.2 ± 0.44 | 29.3 ± 0.42 | 19.2 ± 0.37 | 25.4 ± 0.40 | 36.1 ± 0.34 | 21.3 ± 0.41 |
Results are expressed as zone of inhibition (ZOI). Data is represented as mean ± SEM, (n = 3).
Keys:
P. m Proteus mirabilis, S. a Streptococcus aureus, E. c Escherichia coli, B. c Bacillus cereus, S. t Salmonella typhi, K. p Klebsiella pneumonia, P. a Pseudomonas aeruginosa, E. f Enterococcus faecalis, Ir.Cr Crude methanolic extract, Ir.Hex n-hexane fraction, Ir.Cf Chloroform fraction, Ir.EtAc Ethyl acetate fraction, Ir.Aq Aqueous fraction, Ir.Sp Saponins, Ir.Fl Flavonoids, Ceft Ceftriaxone
Minimum inhibitory concentrations for different fractions of Isodon rugosus against the tested bacterial strains expressed as μg/ml
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| Ir.Cr | 6.66 ± 0.83 | 2.50 ± 0.00 | 8.33 ± 0.83 | 2.66 ± 1.30 | 12.50 ± 2.88 | 8.33 ± 0.83 | 4.16 ± 1.66 |
| Ir.Hex | 18.33 ± 0.83 | 16.66 ± 0.83 | 2.83 ± 1.16 | 1.33 ± 0.60 | 8.33 ± 2.20 | 10.83 ± 2.20 | 12.50 ± 1.44 |
| Ir.Cf | 2.50 ± 0.00 | 3.66 ± 1.96 | 1.00 ± 0.00 | 5.33 ± 2.60 | 2.01 ± 0.50 | 1.16 ± 0.66 | 2.50 ± 0.00 |
| Ir.EtAc | 7.50 ± 1.44 | 7.50 ± 1.44 | 4.16 ± 0.83 | 2.83 ± 1.16 | 3.33 ± 0.83 | 1.33 ± 0.60 | 2.83 ± 1.16 |
| Ir.Aq | 9.16 ± 0.83 | 11.66 ± 0.83 | 10.00 ± 1.44 | 10.83 ± 2.20 | 7.50 ± 1.44 | 5.00 ± 1.44 | 5.00 ± 1.44 |
| Ir.Sp | 1.00 ± 0.00 | 0.83 ± 0.16 | 5.00 ± 1.44 | 2.50 ± 0.00 | 4.50 ± 1.89 | 1.00 ± 0.00 | 3.33 ± 0.83 |
| Ir.Flv | 2.83 ± 1.16 | 1.00 ± 0.00 | 1.50 ± 0.50 | 6.66 ± 2.20 | 2.00 ± 0.50 | 2.66 ± 1.30 | 5.00 ± 1.44 |
| Ceftriaxone | 0.50 ± 0.00 | 0.66 ± 0.16 | 2.50 ± 0.00 | 0.83 ± 0.16 | 0.66 ± 0.16 | 0.50 ± 0.00 | 1.33 ± 0.60 |
Data is represented as mean ± SEM, (n = 3)
Keys:
P. m Protius mirabilis, S. a Streptococcus aureus, E. c Escherichia coli, B. c Bacillus cereus, S. t Salmonella typhi, K. p Klebsiella pneumonia, P. a Pseudomonas aeruginosa, E. f Enterococcus faecalis, Ir.Cr Crude methanolic extract, Ir.Hex n-hexane fraction, Ir.Cf Chloroform fraction, Ir.EtAc Ethyl acetate fraction, Ir.Aq Aqueous fraction, Ir.Sp Saponins, Ir.Fl Flavonoids
Anthelmintic activity of aerial part of Isodon rugosus against Pheretima posthuma and Ascaridia galli
| Samples | Concentration (mg/ml) |
|
| ||
|---|---|---|---|---|---|
| Paralysis time in Minutes (mean ± SD) | Death time in Minutes (mean ± SD) | Paralysis time in Minutes (mean ± SD) | Death time in Minutes (mean ± SD) | ||
| Ir.Cr | 10 | 24.33 ± 1.15*** | 67.00 ± 2.00*** | 20.25 ± 0.57*** | 69.39 ± 0.60*** |
| 20 | 18.67 ± 1.53** | 60.00 ± 2.00*** | 17.01 ± 0.46*** | 61.18 ± 0.67*** | |
| 40 | 11.33 ± 1.56ns | 40.67 ± 1.53*** | 13.48 ± 0.52*** | 53.19 ± 0.36*** | |
| Ir.Hex | 10 | 23.33 ± 2.08*** | 67.33 ± 2.08*** | 28.89 ± 0.52*** | 87.34 ± 0.78*** |
| 20 | 17.00 ± 1.00* | 62.33 ± 1.53*** | 17.32 ± 0.96*** | 71.36 ± 0.56*** | |
| 40 | 11.67 ± 1.53ns | 49.00 ± 1.00*** | 3.43 ± 0.67** | 56.63 ± 0.38*** | |
| Ir.Cf | 10 | 14.00 ± 1.00ns | 50.00 ± 1.00ns | 14.53 ± 0.67ns | 53.01 ± 0.44*** |
| 20 | 10.00 ± 2.00ns | 37.67 ± 1.53ns | 11.95 ± 0.34ns | 41.77 ± 0.40ns | |
| 40 | 7.33 ± 1.53ns | 30.67 ± 2.52ns | 9.85 ± 0.50ns | 34.39 ± 0.55ns | |
| Ir.EtAc | 10 | 18.00 ± 2.00ns | 52.00 ± 2.00ns | 18.13 ± 0.49*** | 58.37 ± 1.16*** |
| 20 | 13.00 ± 2.00ns | 45.00 ± 2.00* | 13.63 ± 0.40** | 49.31 ± 0.82*** | |
| 40 | 10.00 ± 2.00ns | 38.67 ± 1.53** | 10.29 ± 0.56* | 42.25 ± 0.89*** | |
| Ir.Aq | 10 | 21.00 ± 2.00** | 61.00 ± 2.00*** | 19.66 ± 0.88*** | 68.54 ± 0.81*** |
| 20 | 19.00 ± 2.00** | 56.00 ± 2.00*** | 15.4 ± 0.61*** | 57.15 ± 0.85*** | |
| 40 | 15.00 ± 2.00** | 47.67 ± 1.53*** | 13.40 ± 0.69*** | 52.85 ± 0.50*** | |
| Ir.Sp | 10 | 13.33 ± 1.53ns | 44.00 ± 2.00ns | 8.40 ± 0.9*** | 43.00 ± 1.00** |
| 20 | 9.00 ± 2.00ns | 33.67 ± 3.05ns | 8.33 ± 0.58ns | 32.79 ± 0.54*** | |
| 40 | 5.67 ± 1.53ns | 27.67 ± 1.53ns | 4.33 ± 0.58ns | 29.22 ± 0.61** | |
| Albendazole | 10 | 12.33 ± 2.08 | 48.67 ± 1.53 | 13.10 ± 1.85 | 47.40 ± 1.50 |
| 20 | 10.33 ± 2.57 | 37.33 ± 1.53 | 9.80 ± 1.60 | 40.20 ± 2.25 | |
| 40 | 7.00 ± 2.00 | 28.67 ± 1.53 | 7.10 ± 1.01 | 33.60 ± 1.76 | |
| Negative control | ----- | ----- | ----- | ----- | ------ |
Values significantly different (*: P < 0.05, ** P < 0.01 and *** P < 0.001) as compared to positive control drug. ns: Non significantly different in comparion to control group
Keys:
Ir.Cr Crude methanolic extract, Ir.Hex n-hexane fraction, Ir.Cf Chloroform fraction, Ir.EtAc Ethyl acetate fraction, Ir.Aq Aqueous fraction, Ir.Sp Saponins.
Fig. 4Percent lethality of various samples of Isodon rugosus against Rhyzopertha dominica
Fig. 5Percent lethality of various samples of Isodon rugosus against Tribolium castaneum
Anti-termite effect of various samples of Isodon rugosus
| Samples | Number of Termites treated | Days | Percent lethality (mean ± SEM) |
|---|---|---|---|
| Ir.Cr | 25 | 1 | 45.00 ± 1.15*** |
| 2 | 77.32 ± 1.32*** | ||
| 3 | 100.0 ± 0.00ns | ||
| Ir.Hex | 25 | 1 | 50.33 ± 0.88*** |
| 2 | 69.32 ± 1.32*** | ||
| 3 | 100.0 ± 0.00ns | ||
| Ir.Cf | 25 | 1 | 77.32 ± 1.32*** |
| 2 | 96.67 ± 1.20ns | ||
| 3 | 100.0 ± 0.00ns | ||
| Ir.EtAc | 25 | 1 | 93.00 ± 0.57ns |
| 2 | 100.0 ± 0.00ns | ||
| 3 | 100.0 ± 0.00ns | ||
| Ir.Aq | 25 | 1 | 48.33 ± 0.88*** |
| 2 | 74.00 ± 0.57*** | ||
| 3 | 100.0 ± 0.00ns | ||
| Ir.Sp | 25 | 1 | 100.0 ± 0.00ns |
| 2 | 100.0 ± 0.00ns | ||
| 3 | 100.0 ± 0.00ns | ||
| Permethrin | 25 | 1 2 3 | 100.0 ± 0.00100.0 ± 0.00100.0 ± 0.00 |
Data is represented as mean ± SEM; (n = 3). Values significantly different (*** P < 0.001) as compared to the control drug
Keys:
Ir.Cr Crude methanolic extract, Ir.Hex n-hexane fraction, Ir.Cf Chloroform fraction, Ir.EtAc Ethyl acetate fraction, Ir.Aq Aqueous fraction, Ir.Sp Saponins
Anti-Pharaoh ant effect of various samples of Isodon rugosus
| Samples | Dose (mg/ml) | Total treated | No. repeated | Mortality(%) mean ± SEM | LD50 (mg/ml) |
|---|---|---|---|---|---|
| Ir.Cr | 0.5 | 20 | 3 | 41.33 ± 0.88*** | 0.85 |
| 1 | 20 | 52.00 ± 0.57*** | |||
| 2 | 20 | 57.67 ± 0.67*** | |||
| 4 | 20 | 58.00 ± 0.57*** | |||
| 6 | 20 | 70.00 ± 0.00*** | |||
| 8 | 20 | 81.33 ± 0.88*** | |||
| Ir.Hex | 0.5 | 20 | 3 | 39.67 ± 1.20*** | 1.13 |
| 1 | 20 | 49.00 ± 1.15*** | |||
| 2 | 20 | 53.00 ± 0.57*** | |||
| 4 | 20 | 56.67 ± 0.67*** | |||
| 6 | 20 | 58.00 ± 0.57*** | |||
| 8 | 20 | 80.67 ± 1.20*** | |||
| Ir.Cf | 0.5 | 20 | 3 | 67.33 ± 1.45*** | <0.1 |
| 1 | 20 | 68.67 ± 0.67*** | |||
| 2 | 20 | 73.33 ± 0.88*** | |||
| 4 | 20 | 76.00 ± 1.15*** | |||
| 6 | 20 | 85.00 ± 0.57** | |||
| 8 | 20 | 95.33 ± 0.88ns | |||
| Ir.EtAc | 0.5 | 20 | 3 | 72.00 ± 1.15 *** | <0.1 |
| 1 | 20 | 77.67 ± 0.67 *** | |||
| 2 | 20 | 80.33 ± 0.33** | |||
| 4 | 20 | 86.33 ± 0.88* | |||
| 6 | 20 | 90.67 ± 0.67ns | |||
| 8 | 20 | 100.0 ± 0.57ns | |||
| Ir.Aq | 0.5 | 20 | 3 | 29.00 ± 1.15*** | 3.37 |
| 1 | 20 | 41.33 ± 0.88 *** | |||
| 2 | 20 | 44.67 ± 1.20*** | |||
| 4 | 20 | 53.33 ± 0.33 *** | |||
| 6 | 20 | 66.00 ± 0.57*** | |||
| 8 | 20 | 80.67 ± 1.76*** | |||
| Ir.Sp | 0.5 | 20 | 3 | 96.33 ± 0.88ns | <0.1 |
| 1 | 20 | 100.0 ± 0.00ns | |||
| 2 | 20 | 100.0 ± 0.00ns | |||
| 4 | 20 | 100.0 ± 0.00ns | |||
| 6 | 20 | 100.0 ± 0.00ns | |||
| 8 | 20 | 100.0 ± 0.00ns | |||
| Permithrin | 0.5 | 20 | 3 | 93.33 ± 4.40 | <0.1 |
| 1 | 20 | 98.33 ± 1.66 | |||
| 2 | 20 | 100.0 ± 0.00 | |||
| 4 | 20 | 100.0 ± 0.00 | |||
| 6 | 20 | 100.0 ± 0.00 | |||
| 8 | 20 | 100.0 ± 0.00 | |||
| Distilled Water | Negative control | 20 | 3 | 0.00 | 0.00 |
Data is represented as mean ± SEM; (n = 3). Values significantly different (*: P < 0.05, ** P < 0.01 and *** P < 0.001) as compared to the control drug
Keys:
Ir.Cr Crude methanolic extract, Ir.Hex n-hexane fraction, Ir.Cf Chloroform fraction, Ir.EtAc Ethyl acetate fraction, Ir.Aq Aqueous fraction, Ir.Sp Saponins.